Catera Bentley had been trying to conceive for over two years. Her doctor in Steele, Alabama, had informed her that conception was unlikely due to her history of polycystic ovarian syndrome (PCOS), a hormonal disorder that subtly impairs fertility for millions of women. She had become accustomed to a certain type of grief, the kind that comes gradually rather than all at once. After that, she began taking Mounjaro to lose weight.
About 40 pounds were lost. watched as her long, erratic, and unpredictable cycles gradually returned to normal. And one morning, she called her husband at work and informed him of a spider emergency while staring at a third pregnancy test to confirm the results of the first two. Instead, he found her holding the test when he hurried home.
| Category | Details |
|---|---|
| Drug Class | GLP-1 receptor agonists (glucagon-like peptide-1) — originally developed for type 2 diabetes |
| Key Brand Names | Ozempic and Wegovy (semaglutide, by Novo Nordisk); Mounjaro and Zepbound (tirzepatide, by Eli Lilly) |
| FDA-Approved Uses | Type 2 diabetes management and chronic weight management in adults with obesity |
| Average Weight Loss in Trials | Patients lost 15%–20% of total body weight on average in clinical trials |
| Prevalence | 1 in 8 U.S. adults has taken a GLP-1 receptor agonist, according to recent polling |
| Fertility Connection | Weight loss and improved insulin control from GLP-1 drugs can restore regular ovulation, rebalance estrogen, and reduce androgen levels — especially in women with PCOS |
| PCOS Relevance | PCOS affects up to 15% of women of reproductive age and is one of the leading causes of female infertility |
| Birth Control Interaction | Tirzepatide (Mounjaro/Zepbound) reduced oral contraceptive hormone plasma levels by up to 66% and delayed absorption by up to 4.5 hours in studies |
| FDA Pregnancy Guidance | Recommends stopping GLP-1 drugs at least two months before planned pregnancy; advise discontinuing while breastfeeding |
| Safety During Pregnancy | No comprehensive clinical trial data exists; a 2023 observational study of 50,000 pregnant women found no statistically significant rise in major birth defects among 900+ GLP-1 users |
| Manufacturer Registries | Both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) are building pregnancy registries to track maternal and infant health data |
| Men & Fertility | Some research suggests GLP-1 drugs may improve semen concentration, motility, and morphology in men with obesity |
For the past two years, stories like Bentley’s have been building up on social media under hashtags like #OzempicBaby, gaining the kind of viral momentum that usually comes before the science. Now known as “Ozempic babies,” the phenomenon lies at a genuinely complex intersection of metabolic health, reproductive medicine, pharmaceutical side effects, and the unintended consequences of popular drugs. It’s still unclear whether this represents a baby boom in any quantifiable demographic sense. However, it’s getting more difficult to ignore the underlying biology that underlies these tales and what it subtly reveals about the connection between metabolism, weight, and fertility.
GLP-1 receptor agonists, a class of medications that includes tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy), were created to control blood sugar in individuals with type 2 diabetes by imitating a natural gut hormone that slows gastric emptying, alerts the brain to fullness, and increases the production of insulin after meals. In those early trials, the weight loss was essentially a secondary finding that eventually took center stage. The impact that significant weight loss would have on the hormonal architecture of women who had battled infertility for years, especially those with PCOS and obesity, was something that no one fully expected.
Although the specifics are still being worked out, the mechanism isn’t exactly mysterious. The downstream hormonal effects can be substantial when obese women lose about 10% of their body weight: estrogen levels rebalance, androgen levels decrease, and ovulation, which had been irregular or suppressed, starts to return to regularity. The metabolic benefits of GLP-1 medications appear to solve multiple issues at once for women with PCOS, where insulin resistance and high testosterone are already impeding reproduction. These medications may be helping some patients conceive more than years of other treatments were able to. Even though doctors are cautious about how they phrase it, it’s a powerful idea.
Another wrinkle is not getting as much attention as it ought to. The dual-action medication tirzepatide, which is the source of Mounjaro and Zepbound, seems to slow stomach emptying more significantly than semaglutide. This distinction is important for people who use oral contraceptives. According to research, tirzepatide can postpone the peak absorption of oral birth control hormones by up to 4.5 hours and lower their plasma concentration by up to 66%. The interaction is noticeable even at lower dosages. The FDA now specifically advises women starting tirzepatide to include a backup method of contraception both when starting the medication and each time they increase their dosage. It’s advice that hasn’t reached everyone who needs it, based on the number of unintended pregnancies being reported.
According to research reviewed by Samford University pharmacist Jessica Skelley, semaglutide seems to interfere less with oral contraceptives than tirzepatide; however, Novo Nordisk still cautions against taking any oral medication with it. When the entire class is grouped together under the Ozempic name, the subtle differences between various GLP-1 medications on this specific question are blurred.
What happens when these pregnancies unexpectedly continue into the first trimester is still a true mystery. Pregnant women have historically been excluded from clinical trials, so the safety information that would typically reassure physicians and patients is currently unavailable. It is encouraging, if not conclusive, that a 2023 observational study that tracked over 50,000 pregnant women with type 2 diabetes found no statistically significant difference in birth defect rates among those who had been taking GLP-1 medications. Eli Lilly and Novo Nordisk are currently keeping pregnancy registries to monitor results, creating the body of evidence that ought to have been established sooner.
As I watch this happen, there’s something about it that seems almost symbolic: a medication created for a specific purpose subtly changing the lives of people who never asked it to. The surprise has a different significance for women who had given up on becoming pregnant. It carries a completely different kind for women who weren’t trying. It turns out that the body maintains its own computations, and occasionally a new variable causes everything to change.
